Alkermes
artistry cohort enrollment completed | Alkermes
Company
Deck Type
Sector
Industry
Deck date
June 2021
Slide
11 of 31
Similar slides by Alkermes
See diffirences between slides (animation)
Investor Day
March 2021
artistry melanoma cohort focused on unmet need key inclusion criteria artistry study melanoma cohort progressed on immune inhibitor anti with or without anti targeted agent as appropriate inhibitor if protocol defined efficacy response criteria achieved triggered two stage expansion cohort second stage of enrollment underway artistry two stage stage enroll more if stage refractory melanoma expansion total | Alkermes
Related slides by other companies
Nuscale
SPAC
December 2021
key enabling features dependent on patented technology | Nuscale
Aeva
Results
May 2022
aeries on track | Aeva
Immatics
Investor Presentation
November 2023
interim update | Immatics
Kore
Results
August 2022
in vehicle video solutions fleet cam fleet plus kore | Kore
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io